Compare Amgen, Inc. (AMGN) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Harmony Gold Mining Co. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Harmony Gold Mining Co. trades at $15.12 (market cap $9.43B). The key difference: Amgen, Inc. is far larger — about 20.8× Harmony Gold Mining Co.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | HMY | |
|---|---|---|
Market Cap | $196.12B | $9.43B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $26.04 |
52-Week Low | $271.18 | $12.61 |
Enterprise Value | $241.41B | $9.77B |
Dividend Yield | 2.77% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Harmony Gold Mining (HMY) trades at $15.11, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2024 results with $61.38B revenue and $8.59B net income, showing improved margins. Recent earnings have been mixed, beating in Q2 2025 but missing in Q4 2025. A dividend of $0.31 is scheduled for May 2026. Analyst consensus is predominantly Hold (70%), with 10% Buy and 20% Sell ratings.
HMY presents a valuation opportunity with a low P/E of 9.67 and EV/EBITDA of 5.06, supported by robust profitability metrics like 20.06% net margin and 32.32% ROE. However, risks include gold price sensitivity to Fed rate hikes, operational execution in transitioning to gold-copper hybrid model, and bearish technical trends. The stock's outlook balances fundamental strength against macroeconomic and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
